Safety outcomes of anti-platelet therapy post coronary artery bypass graft surgery: A systematic review and network meta-analysis of randomized control trials.
Syed Umar HasanAlina PervezArshad A ShahSyed DA ShahMuhammad AslamAnosha ArshadAmna S RajputM Mujeeb ZubairPublished in: Perfusion (2023)
No significant difference was found between monotherapy or dual-antiplatelet therapy for the major bleeding risk safety outcome, however DAPT was found to have a significantly higher rate of minor bleeding complications post-CABG. DAPT should be considered as the antiplatelet modality of choice post-CABG.
Keyphrases
- coronary artery bypass
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- coronary artery bypass grafting
- atrial fibrillation
- coronary artery disease
- open label
- clinical trial
- double blind
- randomized controlled trial
- type diabetes
- stem cells
- adipose tissue
- minimally invasive
- metabolic syndrome
- insulin resistance
- decision making